Integrated proteomic and phosphoproteomic studies have demonstrated that targeting sterol O-acyltransferase 1 (SOAT1) to lower plasma membrane cholesterol content offers a promising therapeutic approach for early-stage HCC, as validated in patient-derived xenograft mouse models (51). The gene discussed is SOAT1; the disease is hepatocellular carcinoma.